An Emerging Role for Serine Protease Inhibitors in T Lymphocyte Immunity and Beyond
ISRN Immunology · 2012
DOI: 10.5402/2012/354365 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Immunology, 2012. Verfasst von Philip G. Ashton-Rickardt. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
The serine proteases of T lymphocytes provide immunity to infection. Serine Proteases Inhibitors (serpins) control the recognition of antigen, effector function, and homeostatic control of T lymphocytes through the inhibition of serine protease targets. Serpins are important promoters of cellular viability through their inhibition of executioner proteases, which affects the survival and development of long-lived memory T cells. The potent antiapoptotic properties of serpins can also work against cellular immunity by protecting viruses and tumors from eradication by T lymphocytes. Recent insights from knockout mouse models demonstrate that serpins also are required for hematological progenitor cells and so are critical for the development of lineages other than T lymphocytes. Given the emerging role of serpins in multiple aspects of lymphocyte immunity and blood development, there is much potential for new therapeutic approaches based directly on serpins or knowledge gained from identifying their physiologically relevant protease targets.
Förderung
- National Institutes of Health
Zitieren
APA
Ashton-Rickardt, P. G. (2012). An Emerging Role for Serine Protease Inhibitors in T Lymphocyte Immunity and Beyond. ISRN Immunology. https://doi.org/10.5402/2012/354365
Vancouver
Ashton-Rickardt PG. An Emerging Role for Serine Protease Inhibitors in T Lymphocyte Immunity and Beyond. ISRN Immunology. 2012. doi:10.5402/2012/354365
BibTeX
@article{AshtonRickardt2012,
author = {Ashton-Rickardt, Philip G.},
title = {An Emerging Role for Serine Protease Inhibitors in T Lymphocyte Immunity and Beyond},
journal = {ISRN Immunology},
year = {2012},
doi = {10.5402/2012/354365}
}
EUVIMED